| Therapeutics | Personalized Medicine | Medical Technologies | Industrial Biotechnology | Healthcare Services |


Aerie Pharmaceuticals

Aerie (Nasdaq: AERI)

A clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye. The product candidates are once-daily, well-tolerated eye drops designed to provide eye-care professionals with the first novel intraocular pressure-lowering mechanisms of action, or MOAs, to treat glaucoma in over 20 years.



Albireo is a spin-out from Astrazeneca located in Gothenburg Sweden. Albireo is a clinical stage company developing novel therapies that address unmet medical needs in the GI and hepatology areas, specifically chronic constipation and cholestatic liver disease.


Alder (Nasdaq: ALDR)

Alder uses its proprietary technologies to uniquely identify, develop, produce and market its own antibody therapeutics. The work being done at Alder today will potentially help those who suffer from migraine, autoimmune diseases, and inflammatory diseases.

AXCAN Pharma

Aptalis Pharma (Acquired by Forest Laboratories)

Aptalis is a specialty pharmaceutical company that markets a portfolio of branded drug products and develops new medicines to treat patients suffering from GI diseases and cystic fibrosis. The company acquires product rights for development and commercialization through licensing, collaborative partnerships and targeted mergers and acquisitions to take advantage of attractive late-stage development and commercial opportunities.


Avidia (Acquired by Amgen in 2006)

Avidia Research Institute develops and manufactures human therapeutic proteins known as avimers. Avidia engineers these avimer drugs against multiple validated and novel targets to address different disease areas, including inflammation, oncology and neurology.


BioCryst (Nasdaq: BCRX)

BioCryst designs, optimizes and develops novel small-molecule drugs that block key enzymes involved in infectious and inflammatory diseases. BioCryst uses state-of-the-art structure-guided drug design, which incorporates multiple scientific disciplines including biology, crystallography, medicinal chemistry and computer modeling, in order to most efficiently develop new therapeutic candidates.

Collegium Pharmaceutical

Collegium Pharmaceutical (Nasdaq: COLL)

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its patent-protected DETERx technology platform for the treatment of chronic pain. The DETERx oral drug delivery technology is designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options.

Elevation Pharmaceuticals

Elevation Pharmaceuticals (Acquired by Sunovion in 2012)

Founded in 2008, Elevation Pharmaceuticals is developing a pipeline of improved aerosol drug products for COPD patients. The founding team has a successful track record of starting companies and building dedicated teams to develop new drug products that improve patients' lives.



Enlibrium is developing novel drugs based on metformin to treat a range of different cancers by reducing cancer energy consumption and reestablishing energy balance. Given their high growth rate and energy requirements, cancers are particularly sensitive to agents that reduce their energy production.


Epirus (Nasdaq: EPRS)

Epirus is building a global biosimilar enterprise to improve patient access to important medicines. The Company’s strategy for commercial success relies on targeted approaches for diverse global markets. For emerging markets with accessible regulatory frameworks for biosimilars, Epirus develops partnerships with local companies to accelerate regulatory approval and commercialize its products.


Five Prime (Nasdaq: FPRX)

Five Prime is a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases. Five Prime has developed a library of more than 5,700 human extracellular proteins. Five Prime screens this comprehensive library with its proprietary high-throughput protein screening technologies to identify new targets for protein therapeutics.


FoldRx (Acquired by Pfizer in 2010)

Focused on the discovery, development and commercialization of small molecule therapeutics for disease modification of disorders of protein folding and protein homeostasis. The company was founded based on technology developed at the Scripps Institute (San Diego) and the Whitehead Institute (MIT/Cambridge).



Galleon is the first company to build a drug discovery and development platform that focuses on the pharmaceutical treatment of sleep apnea and related breathing-control disorders. The company’s proprietary platform incorporates recent advances in neurobiology, molecular physiology, respiratory medicine and medicinal chemistry. The Company has developed proprietary models of sleep apnea and breathing control that enable a multi-dimensional analysis of the primary causes of sleep apnea and related conditions.


JCR (Tokyo: 4552)

JCR Pharmaceuticals is a Japanese company that focuses on high value follow-on biologics. JCR is a profitable company with fully integrated capabilities, including state of the art production facilities in Japan. Two of JCR’s major commercial products are Growject® (human growth hormone), and a follow-on biologic version of erythropoietin. JCR Pharmaceuticals was established in 1975 and is traded on the Tokyo Stock Exchange.


Karos Pharmaceuticals

Karos Pharmaceuticals is a pharmaceutical company focused on pulmonary arterial hypertension and other orphan diseases.

Macro Genics

MacroGenics (Nasdaq: MGNX)

MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. The Company generates its pipeline of product candidates from its proprietary suite of next-generation antibody technology platforms, which the Company believes improve the performance of monoclonal antibodies and antibody-derived molecules.


Otonomy (Nasdaq: OTIC)

Otonomy is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear. Otonomy's proprietary technology provides sustained exposure of drugs to the middle and inner ear following a single intratympanic (IT) injection. Otonomy has three product candidates in development, including AuriPro, an antibiotic that has completed Phase 3 clinical trials in pediatric patients with middle ear effusion at the time of tympanostomy tube placement surgery.

Par Pharmaceutical

Par Pharmaceutical

Par Pharmaceutical Companies, Inc. is a privately held, U.S.-based specialty pharmaceutical company that develops, manufactures and markets high barrier-to-entry generic drugs and niche, innovative proprietary pharmaceuticals through its three operating divisions, Par Pharmaceuticals, Par sterile products and Strativa Pharmaceuticals.

Trevi Therapeutics

Trevi Therapeutics

Trevi Therapeutics, Inc. is a clinical stage biotechnology company focused on developing Nalbuphine ER for chronic pruritus (itch). The Company is pursuing two conditions for clinical development: uremic pruritus and prurigo nodularis. Uremic pruritus is a persistent and debilitating itch in patients on dialysis that has been associated with increased mortality. Prurigo nodularis is a chronic dermatologic condition characterized by severely pruritic nodules on the skin that are independent of underlying etiology. There are no approved therapies in the US or EU for either condition.


Ultragenyx (Nasdaq:RARE)

Ultragenyx is a clinical-stage biotechnology company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies.



Virobay is focused on the development and commercialization of novel drugs through the utilization of small molecule inhibitors of cysteine proteases, a diverse class of enzyme proteases, for a variety of conditions, including neuropathic pain, autoimmune diseases and fibrosis. The foundation of Virobay’s proprietary cathepsin platform and the Virobay management team were spun-out from Celera Genomics, which was then a leader in cathepsin research. Virobay’s clinical pipeline currently includes product candidates in neuropathic pain, dermatology, autoimmune disease and fibrosis.

   Personalized Medicine



CardioDx is a molecular diagnostics company specializing in cardiovascular genomics, is committed to developing clinically validated tests that empower clinicians to better tailor care to each individual patient. Strategically focused on coronary artery disease, cardiac arrhythmia and heart failure, CardioDx is committed to expanding patient access and improving healthcare quality and efficiency through the commercialization of genomic technologies.


CareDx (Nasdaq: CDNA)

CareDx is a molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value, non-invasive diagnostic surveillance solutions for transplant recipients. The company has commercialized AlloMap, a gene expression test that aids clinicians in identifying heart transplant recipients with stable graft function.



Immucor is a global leader in transfusion and transplantation diagnostics that facilitate patient-donor compatibility. Their mission is to ensure that patients in need of blood, organs or stem cells get the right match that is safe, accessible and affordable.

Genomic Health

Genomic Health (Nasdaq: GHDX)

Genomic Health, Inc. is the world's leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early stage cancer. Genomic Health's lead product, the Oncotype DX® breast cancer test, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer and has been shown to predict the likelihood of recurrence in ductal carcinoma in situ (DCIS). In addition to this widely adopted test, Genomic Health provides the Oncotype DX colon cancer test, the first multi-gene expression test developed for the assessment of risk of recurrence in patients with stage II and stage III disease, and the Oncotype DX prostate cancer test, which predicts disease aggressiveness in men with low risk disease.



Nodality is advancing drug discovery, therapeutic development, and precision medicine by delivering critical and clinically actionable information to bridge gaps left by traditional R&D approaches. Nodality's proprietary functional biology platform, Single Cell Network Profiling (SCNP), unlocks highly complex intracellular mechanisms and cellular interactions in human diseases and has the power to shed light on some of the pharmaceutical industry's most challenging R&D problems.



NovaSom is a leader in Obstructive Sleep Apnea (OSA) home testing, with the AccuSom® home sleep test, the only comprehensively supported home sleep test that provides continuous patient support and next-day test results and interpretation for health care professionals. The FDA-cleared AccuSom® is as accurate as sleep lab testing, and significantly more convenient and comfortable for patients. Patients are able to test around their own schedule and can sleep in their own bed, which helps eliminate “first night” effect and improves data collection. AccuSom® is currently covered for more than 150 million commercially insured U.S. lives.



Progyny, Inc. is the new combined entity of Auxogyn, Inc. and Fertility Authority, LLC.

Progyny provides fertility patients with easy accessibility to high quality doctors, price transparency, and financing, coupled with extraordinary clinical expertise and proprietary clinical solutions. Rooted in clinical knowledge and serving as a champion for the consumer, the company is committed to helping ensure that patients control their fertility journey and achieve the best possible outcome.


Roka (Nasdaq: ROKA)

Roka Bioscience is a molecular diagnostics company focused on developing and commercializing advanced testing solutions for the food safety testing market. The Atlas Detection Assays incorporate advanced molecular technologies and are performed on a "sample-in, result-out" Atlas System that automates all aspects of molecular diagnostic testing on a single, integrated platform. The Atlas System and Detection Assays are designed to provide customers with accurate and rapid test results with reduced labor costs and improved laboratory efficiencies.


Veracyte (Nasdaq:VCYT)

Veracyte is pioneering the field of molecular cytology, focusing on genomic solutions that resolve diagnostic ambiguity and enable physicians to make more informed treatment decisions at an early stage in patient care. By improving preoperative diagnostic accuracy, the company aims to help patients avoid unnecessary invasive procedures while reducing healthcare costs. Veracyte's first commercial solution, the Afirma® Thyroid FNA Analysis, provides a comprehensive approach for assessing thyroid nodules, centered on the proprietary Gene Expression Classifier (GEC) to resolve ambiguity in diagnosis. Backed by multiple, peer-reviewed, published studies and included in leading medical guidelines, Afirma is covered by Medicare and major commercial payers, which collectively represent more than 135 million covered lives.

   Medical Technologies


Tandem (Nasdaq: TNDM)

Tandem Diabetes Care, Inc. is a medical device company with an innovative, user-centric and integrated approach to the design, development and commercialization of products for people with insulin-dependent diabetes. The Company manufactures and sells the t:slim Insulin Pump, the slimmest and smallest durable insulin pump currently on the market, and the first and only insulin pump with a high resolution, color touch screen.

   Industrial Biotechnology


AgraQuest (Acquired by Bayer in 2012)

AgraQuest is focused on becoming the leading provider of natural pesticides, fungicides and herbicides. There is a surge in focus on consumer health, and there are several very large market opportunities in the conventional, organic and retail markets for biopesticides.


Agria (NYSE: GRO)

Agria is a global agricultural company with three principal business segments: Seed & Grain; Crop Protection, Nutrients & Merchandise; and Rural Services. The Seed and Grain segment is engaged in research and development, production and sale of a broad range of seed products and trading of seed and grain products globally. The Crop Protection, Nutrients and Merchandise segment operates an extensive chain of retail stores that supply farm input materials. The Rural Services segment provides livestock trading, wool trading, irrigation and pumping, real estate agency and other agriservices.

Alphabet Energy

Alphabet Energy

Alphabet Energy makes waste heat valuable by developing the first turnkey thermoelectric generators for waste-heat recovery. Their low- cost products reduce operating costs and deliver short payback times by turning waste heat from exhaust into electricity, improving fuel efficiency and reducing operating costs with devices that are easy to install and require no maintenance.


Amyris (Nasdaq: AMRS)

Amyris is an integrated renewable products company focused on providing sustainable alternatives to a broad range of petroleum-sourced products. Amyris uses its industrial bioscience technology platform to convert plant sugars into a variety of molecules -- flexible building blocks that can be used in a wide range of products. Amyris's initial portfolio of commercial products is based on Biofene®, Amyris's brand of renewable farnesene, a long-chain hydrocarbon. Amyris is commercializing these products both as No Compromise® renewable ingredients in cosmetics, flavors and fragrances, polymers, lubricants and consumer products, and also as No Compromise renewable diesel and jet fuel.

Beta Renewables

Beta Renewables

Beta Renewables is a leader in the field of advanced biofuels and biochemical compounds at competitive costs. Beta Renewables owns the Proesa™ technology, applied to the field of biofuels and chemical intermediates. Beta Renewables manages the plant in Crescentino, the first commercial facility in the world for the production of second-generation ethanol.



ChemEOR develops and supplies customized chemical products to the oil and natural gas production industry worldwide. It has two flagship product lines, SurFlood line for surfactants and PolyFlood line for polymers. These products are applied to well stimulation, reservoir recovery, and flow assurance in mature fields, shale development, and deep water.



Elevance Renewable Sciences, Inc. is a high-growth specialty chemicals company that creates novel specialty chemicals that perform better from renewable feedstocks, making the products that industry and consumers use every day better. Using a proprietary technology called olefin metathesis, the company helps industry deliver products that exceed the performance of existing products while leaving a smaller environmental footprint — for use in personal care products, detergents and cleaners, engineered polymers, lubricants and additives, and other specialty chemicals markets.



Genomatica is a widely-recognized technology leader for the chemical industry. It develops manufacturing processes that enable its licensee partners to produce the world's most widely-used chemicals a 'better way,' from alternative feedstocks, with better economics and greater sustainability than petroleum-based processes

   Healthcare Services



DNAnexus is powering the genomics revolution with an enterprise-level solution that combines cloud computing with advanced bioinformatics. The DNAnexus team is made up of experts in software, computational biology, and genetics who are on a mission to establish DNAnexus at the center of a growing ecosystem of scientific and clinical research, and diagnostic efforts in personalized medicine.

IMS Health

IMS Health (NYSE: IMS)

IMS Health is a leading global information and technology services company providing clients in the healthcare industry with comprehensive solutions to measure and improve their performance. By applying sophisticated analytics and proprietary application suites hosted on the IMS One intelligent cloud, the company connects more than 10 petabytes of complex healthcare data on diseases, treatments, costs and outcomes to help its clients run their operations more efficiently.


Matrix Laboratories (Acquired by Mylan in 2006)

One of the world's largest manufacturers and suppliers of active pharmaceutical ingredients (APIs) for a wide range of therapeutic categories, including antibacterials, central nervous system agents, antihistamine/anti-asthmatics, cardiovasculars, antivirals, antidiabetics, antifungals, proton pump inhibitors and pain management drugs. Based in Hyderabad, India.


NT Pharma (SEHK: 1011)

NT Pharma Group is the largest third-party promotional and sales services provider of pharmaceuticals and vaccines in China. NT Pharma integrates the distribution, promotion, manufacturing, research and development of pharmaceuticals and vaccines, providing one-stop service for pharmaceuticals and vaccines, with the focus on the research and development of own brand products. NT Pharma's sales network reaches out to 300 cities across the nation, covering 3,800 hospitals, over 2,800 CDCs and more than 20,500 POVs.

Patient Safe Solutions

PatientSafe Solutions

PatientSafe Solutions, based in San Diego, California, is leading the way in smart point-of-care mobile solutions and innovating technologies for the future of accountable care. Its flagship product, PatientTouch™, delivers measureable safety and quality improvement by making care team workflows easier and more productive in the hospital.


Quintiles (NYSE: Q)

Quintiles, a Fortune 500 company, is the world’s largest provider of biopharmaceutical development and commercial outsourcing services. With a network of more than 29,000 employees conducting business in approximately 100 countries, the company helped develop or commercialize all of 2013's top-100 best-selling drugs on the market. Quintiles applies breadth and depth of service offerings along with extensive therapeutic, scientific and analytics expertise to help customers navigate an increasingly complex healthcare environment as they seek to improve efficiency and effectiveness in the delivery of better healthcare outcomes.

Rapid Micro Biosystems

Rapid Micro Biosystems

Rapid Micro Biosystems provides innovative products for faster detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. The Company's Growth Direct™ System detects contamination earlier, delivering compelling economic benefits to manufacturers, while improving their quality process.



ShangPharma Corp is a leading China-based contract research organization (CRO) providing high-quality and cost-effective services for the pharmaceutical and biotechnology industry. The group offers a broad range of high-quality, integrated services across the drug discovery and development process to help international and Chinese pharmaceutical and biotechnology companies discover and develop novel drug candidates efficiently.

Unchained Labs

Unchained Labs

Unchained Labs develops and sells life science tools products after buying businesses and product lines. Unchained’s first product, Optim, is the first and only multiplex protein stability platform for biologics.

Wil Research

WIL Research (Acquired by American Capital in 2007)

WIL Research Laboratories is a contract research organization (CRO) that provides an interdisciplinary approach to toxicology, pharmacology, metabolism, and bioanalytical services to the pharmaceutical, biotechnology, chemical, agricultural, veterinary, and food and consumer products industries.